[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hydration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hydration":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,76,101,139,165,187,208,233],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100642275","the-role-of-carbohydrate-blends-and-electrolytes-on-physical-and-mental-performance-during-cycling-in-the-heat-100642275",false,"NCT07658820","The Role of Carbohydrate Blends and Electrolytes on Physical and Mental Performance During Cycling in the Heat","CARB-HEAT","Inclusion Criteria:\n\n* Healthy and injury free (muscle, skeletal) for greater than 2 months\n* Active cyclists who train at least 3 times per week\n* Body mass index (BMI) range of 18.5-30 kg\u002Fm2\n* VO₂max ≥ 51 mL\u002Fkg\u002Fmin for male participants\n* VO₂max ≥ 45 mL\u002Fkg\u002Fmin for female participants\n\nExclusion Criteria:\n\n* Taking medicine influences the cardiovascular system\n* non-steroidal anti-inflammatory drugs during the last week\n* Cancer Diagnosis during the last 5 years\n* Current Pregnancy\n* History of renal disease, hypertension, obstructive gastrointestinal tract disease, disorders or impairment of the gag reflex, previous gastrointestinal surgery\n* History of heat stroke\n* Use of testosterone therapy\n* Adults who are unable to consent (impaired decision-making capacity)\n* Adults having Felinization of the esophagus\n* Adults who will undergo Nuclear Magnetic Resonance (NMR) or MRI scanning within 3 days of swallowing a temperature sensitive pills",true,"ALL","18 Years","55 Years",{"count":21,"type":22},14,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of the present study is to evaluate the effectiveness of a milk permeate-based sports drink on hydration, carbohydrate oxidation, exercise performance, vigilance, and reaction time in the heat. We anticipate that the milk permeate, with 44 g per liter and high sodium and potassium, will lead to better hydration, energy delivery, and physical and cognitive performance.",[28,29,30],"Hydration","Dehydration (Physiology)","Performance",[32,33],"exercise in the heat","cognitive performance","NOT_YET_RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":37,"type":22},{"date":41,"type":22},"2027-12-31",{"name":43,"class":44},"Arizona State University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100641443","hydration--female-life-stages-100641443","NCT07653620","Hydration & Female Life Stages","Effect of Female Life Stage on Rehydration With Water vs. an Electrolyte Solution After Overnight Fast\u002FFluid Restriction","Inclusion Criteria:\n\n* • Sex assigned female at birth.\n\n  * Recreationally active (engaged in light to moderate-intensity, intermittent, or steady-state exercise at least 3 days per week for at least 30 min at a time)\n  * Age 18-60 years, within the following life stage ranges specified below:\n  * Premenopausal:\n\n    * 18-35 years\n    * Self-report regular spontaneous menstrual cycle length (21-35 days) for the past 2 menstrual cycles\n    * Menstrual cycle length \\\u003C 7 days variation in consecutive cycles\n  * Perimenopausal:\n\n    * Perimenopause: 35-55 years\n    * If tracking cycles: self reported cycle irregularity (≥7 day difference from usual cycle length) for the past 2 menstrual cycles, not due to known pathology\n    * If not tracking cycles: clinician diagnosis\n  * Postmenopausal:\n\n    * Postmenopause: 45-60 years\n    * If tracking cycles: ≥12 consecutive months of spontaneous amenorrhea not due to pregnancy, lactation, or pathology\n    * If not tracking cycles: clinician diagnosis\n  * Healthy, with no known renal, cardiovascular, metabolic, or endocrine disorders that affect hydration or fluid regulation.\n  * Not currently taking medications known to influence fluid balance (e.g., diuretics, laxatives, weight loss agents, or other relevant medications) or the hypothalamus-pituitary-gonadal axis (e.g., ovulation induction agents, gonadotropins, IVF stimulation medications, or other relevant medications)\n\n    o See appendix 13.8 for list of medications, drugs, and\u002For medical conditions that may impair cognitive functioning, alter physiological responses relevant to the study outcomes, or increase the risk associated with participation.\n  * Not receive any fertility treatments within the past 6 months\n  * No hormonal contraceptives use within the past 6 months\n  * If using a paraguard copper IUD, it must be inserted for ≥ 3 months (if applicable)\n  * BMI ≤ 30 kg\u002Fm²\n  * Are not participating in a weight loss program\n  * Are not allergic to adhesives, stevia, and strawberry lime flavoring\n  * Willing to avoid strenuous activity and alcohol consumption 24 hours prior to all visits\n  * Willing to fast overnight (\\~12 hours) prior to the medical screening\n  * For visit 2 and 4:\n\n    * Willing to fast overnight (\\~12 hours)\n    * Willing to consume a minimum of 2.7 L of water 24 hours prior to visits 2 and 4, then 500 mL 2 hours before the start of the visits 2 and 4\n  * For visits 3 and 5:\n  * Willing to restrict all fluids (\\~18 hours)\n  * Willing to limit fluid consumption to 1 L the morning\u002Fafternoon prior to the start of the fluid restriction\n  * Willing to restrict food (\\~12 hours) the day prior to each visit Willing to eat a consistent diet the day prior\n  * Fluent in English (able to read, understand, and provide informed consent).\n  * Willing and able to provide informed consent to participate in the study and comply with all study procedures and scheduled visits\n\nExclusion Criteria:\n\n* • Currently pregnant or breastfeeding\n\n  * \\\u003C 6 months since giving birth (even if experiencing 2 regular menstrual cycles in a row)\n  * Smoking within the last 5 years\n  * History of adverse events (e.g., fainting) with blood draws\n  * Participants with large amount of internal metal (e.g., spinal rod) will be excluded from the DXA scan only (Brandenton)\n  * Participant has participated in a clinical trial within the past 30 days\n  * Participant has participated in any PepsiCo trial within past 3 months\n  * Participant has a condition or is taking medication that the investigator believes would interfere with his\u002Fher ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the person at undue risk\n  * Participant is employed by, or has a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If participant is unsure if a company would be considered a competitor to Gatorade, they will be asked to please let the study investigator know the name of the other company and the nature of their relationship to that company before they sign the informed consent.","FEMALE","60 Years",{"count":56,"type":22},72,[25],"Female life stages including premenopausal, perimenopausal, postmenopausal, are characterized by changing concentrations and patterns of hormones. The premenopause stage represents the reproductive years with normal menstrual cycles lasting between 21-35 days. The perimenopause stage is the beginning of the menopause transition and can last up to 10 years. During this transition, menstrual cycles become longer and irregular in length (7 days or longer). After 12 consecutive months with no period, the transition is complete into the postmenopause stage.\n\nHormones that change across the lifespan are known to influence systems that regulate thirst, fluid balance, and sodium balance. Yet, fluid balance across life stages remains poorly understood, with no direct comparisons across all three life stages. The purpose of this study is to evaluate the effect of female life stage on rehydration with water and electrolyte solution after overnight fast and fluid restriction",[60,61,62,63,64,28],"Dehydration","Menstruation","Pre-menopause","Peri-menopausal Women","Post-menopausal Women","RECRUITING","2026-06-12",{"date":35,"type":38},{"date":69,"type":22},"2026-06",{"date":71,"type":22},"2026-12",{"name":73,"class":74},"PepsiCo Global R&D","INDUSTRY",2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":45},"100643341","effectiveness-and-safety-of-a-hydrating-gel-containing-polyvinyl-pyrrolidine-algin-and-hyaluronic-acid-applied-after-and-without-fractional-co-laser-therapy-100643341","NCT07639151","Effectiveness and Safety of a Hydrating Gel Containing Polyvinyl Pyrrolidine, Algin and Hyaluronic Acid Applied After and Without Fractional CO₂ Laser Therapy","Effectiveness and Safety of a Hydrating Gel Containing Aqua, Carrageenan, Polyvinyl Pyrrolidon, Algin, Gellan Gum, and Hyaluronic Acid Applied After and Without Fractional CO₂ Laser Therapy","Inclusion Criteria:\n\n1. Female participants aged 18-60 years.\n2. Patients attending the Dermatology and Venereology Outpatient Clinic of Universitas Indonesia Hospital (RSUI) who will receive the hydrating gel either following fractional CO₂ laser treatment or without undergoing the fractional CO₂ laser procedure.\n3. Patients who will undergo or have undergone a priming regimen with topical retinoic acid preparations at concentrations of at least 0.025%, 0.05%, or 0.1% for at least 2 weeks prior to fractional CO₂ laser treatment, or prior to study participation in the non-laser group.\n4. Willing to participate in the study and have provided written informed consent after receiving adequate explanation regarding the study.\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding, or currently using oral contraceptives at the time of assessment.\n2. History of systemic retinoid use within the past 3 months.\n3. History of or current treatment for hormonal\u002Fendocrine disorders or other serious medical conditions.\n4. Currently receiving immunosuppressive therapy.\n5. Participants who are unable or unwilling to comply with the study protocol and treatment regimen.",{"count":84,"type":22},51,[25],"The purpose of this interventional study is to evaluate the effectiveness and safety of a hydrating gel containing aqua, carrageenan, polyvinyl pyrrolidone, algin, gellan gum, and hyaluronic acid. The study will assess the gel's ability to support optimal skin recovery following fractional CO₂ laser therapy and its effectiveness and safety as a daily adjunctive skincare treatment. Outcomes related to skin hydration, skin barrier function, tolerability, and adverse events will be evaluated throughout the study period.\n\nFemale participants aged 18 to 60 years who provide informed consent will be enrolled in this study. Participants will undergo a 2-week priming period with topical tretinoin prior to fractional CO₂ laser treatment. Clinical evaluations will be performed at baseline, immediately after the laser procedure, and on Days 3, 7, and 14 post-treatment. Assessments conducted by a board-certified dermatologist will include dermoscopy, TEWAmeter assessment, erythema assessment, and evaluation of pain and discomfort using a Visual Analog Scale (VAS).",[28,88,89,90],"Carbon-dioxide Laser","Laser Therapy","Hydrogel",[90,92,28],"CO2 Fractional Laser","2026-06-05",{"date":95,"type":38},"2026-06-10",{"date":69,"type":22},{"date":98,"type":22},"2026-09",{"name":100,"class":44},"Dr.dr.Irma Bernadette, SpKK (K)",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":16,"sex":108,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":121,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100637590","effects-of-creatine-and-heat-exposure-on-exercise-performance-and-body-water-distribution-100637590","NCT07593014","Effects of Creatine and Heat Exposure on Exercise Performance and Body Water Distribution","Creatine Monohydrate Supplementation During Repeated Heat Exposure: Effects on Fluid Balance and Exercise Performance in a Randomized Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Healthy biological males between 18 and 27 years of age\n* Recreationally active males and varsity athletes\n* Able to safely participate in moderate-intensity exercise and heat exposure\n* Willing to maintain habitual diet and physical activity throughout the study\n* Willing to refrain from additional dietary supplementation during study participation\n* Able to attend all required laboratory visits and heat exposure sessions\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* History of cardiovascular, metabolic, respiratory, renal, neurological, or heat-related illness\n* Contraindications to exercise testing or heat exposure identified during health screening\n* Current musculoskeletal injury limiting exercise participation\n* Current use of creatine supplementation or inability to complete the required washout period\n* Current use of medications or supplements known to affect hydration, thermoregulation, cardiovascular function, or exercise performance\n* Known allergy or intolerance to creatine monohydrate, maltodextrin, or orange juice\n* Inability to comply with study procedures or supplementation protocol\n* Resting tympanic temperature ≥38.0°C prior to a heat exposure session\n* Participation in another research study that may interfere with this protocol","MALE","27 Years",{"count":111,"type":22},25,[25],"The goal of this clinical trial is to learn whether creatine supplementation changes how the body adapts to repeated exercise in the heat in healthy recreationally active adults and varsity athletes. The study will also examine whether creatine affects fluid balance, blood volume changes and exercise performance.\n\nThe main questions it aims to answer are:\n\nDoes creatine supplementation increase plasma volume and total body water during repeated heat exposure more than placebo? Does creatine supplementation improve exercise performance after heat acclimation more than placebo? Does creatine supplementation influence cardiovascular responses to heat stress?\n\nResearchers will compare a creatine supplementation group to a placebo group to determine whether creatine changes the magnitude of heat acclimation adaptations.\n\nParticipants will:\n\nComplete baseline measurements of body composition, hydration, blood markers, and exercise performance.\n\nConsume either creatine monohydrate or a placebo supplement daily Complete repeated supervised exercise sessions in a controlled heated environment Undergo repeated assessments of body water, temperature, heart rate, and exercise performance throughout the study",[115,116,28,117,118,119,120],"Heat Exposure","Exercise Performance","Body Fluid Compartments","Creatine Supplementation","Placebo - Control","Plasma Volume",[122,115,123,124,120,125,117,126,127,128,129],"Creatine Monohydrate","Heat Acclimation","Short Term Heat Acclimation","Fluid Balance","Wingate Test","VO2 Max","Cardiorespiratory Performance","Musculoskeletal Performance","2026-05-11",{"date":132,"type":38},"2026-05-18",{"date":134,"type":22},"2026-07-30",{"date":136,"type":22},"2027-08-30",{"name":138,"class":44},"University of Windsor",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":45},"100631950","beverage-hydration-index-of-different-solutions-100631950","NCT07507344","Beverage Hydration Index of Different Solutions","Comparison of the Beverage Hydration Index of Different Solutions","* Be age 18 years or older\n* male or female\n* have a body mass index (BMI)between 18.5-35 kg\u002Fm2 (not morbidly obese)\n* Be engaged in moderate physical activity, defined as ≤5 hours\u002Fweek of aerobic exercise\n* Not have a history or presence of a clinically relevant (that required or requires treatment) cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorder (reviewed by Nurse practitioner)\n* Not have other conditions that are likely to alter fluid balance or be negatively affected by changing electrolyte levels\u002Fhydration status (as determined by Nurse practitioner)\n* Not be consuming any medication which may alter fluid retention\u002Felectrolyte levels such as Selective Serotonin Reuptake Inhibitors, sodium-glucose co-transporter 2 (SGLT2) inhibitor (for type 2 diabetes), laxatives, diuretics, Apremilast, chemotherapy, or lithium. (Medications will be reviewed by Nurse practitioner)\n* Not consume nutritional supplements, performance enhancing drugs, and\u002For non-steroidal anti-inflammatory drugs within 7 days of study visits excluding screening.\n* Follow the lifestyle and dietary restrictions before study visits (excluding screening\u002Fconsenting visit) including before each visit avoiding strenuous activity for 24 hours prior, refrain from caffeine for 12 hours and alcohol for 24 hours, consume the standardized diet and maintain similar activity levels for 24 hours prior, consume 2.5 liters for men or 2.0 liters for women day prior, and fast (water only) of at least 10 hours prior.\n* Not have a sensitivity or be allergic to any components of the study interventions (water, calcium chloride, magnesium chloride, potassium bicarbonate, magnesium, sodium, chloride, potassium, vitamin C, dextrose, AminoAbsorb (L-alanine, L-glutamine, glycine).\n* Not be a tobacco user\n* Not be following a specialized dietary pattern that may alter findings (e.g., low carbohydrate\u002Fketogenic diet, carnivore diet, intermittent fasting etc.)\n* Arrive to lab for visits euhydrated (USG 1.005-1.020)\n* Have the ability and willingness to fast (consume water\u002Ftreatments only) for 15 hours (10 hours prior to lab visits not including screening)\n* Not be enrolled in another clinical study within 30 days of the first study visit\n* Be without active infection or illness of any kind\n* Not be pregnant or breastfeeding\n* Not have surgery in the previous 4 months",{"count":147,"type":22},30,[25],"In this study, the impact of two electrolyte hydration stick products (Hydramin containing an electrolyte\u002Famino acid formulation and an identical electrolyte product with the amino-acids replaced with carbohydrate, dextrose) dissolved in 1 liter of water will be assessed and compared to a control (1 liter Smart Water). It is hypothesized that the addition of amino acids and glycine should improve the Beverage Hydration Index above water alone and perform comparably to the carbohydrate rich solution.\n\nThis study will focus on general population (not athletes) and follow very similar approaches used in previous studies within the Center for Nutraceutical and Dietary Supplements Research, with the addition of blood glucose testing and body water measurements. Hydration will be assessed via fluid balance (the difference between the amount of water consumed and passed as urine) and calculations of beverage hydration index (the relative amount of urine passed after consumption of a drink compared to water)as well as time in positive fluid balance, and specific gravity, and sodium and potassium in urine. Blood glucose before and following consumption using finger pricks and a glucometer will also be assessed.",[28],[152,153,154,155],"hydration","electrolytes","Hydramin","Beverage Hydration Index","2026-04-01",{"date":158,"type":38},"2026-04-07",{"date":160,"type":38},"2026-02-23",{"date":162,"type":22},"2026-06-30",{"name":164,"class":44},"University of Memphis",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":16,"sex":53,"minAge":172,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":45},"100348978","bioimpedance-in-pregnancy-and-labour-a-fluid-balance-concept-study-100348978","NCT03823820","Bioimpedance In Pregnancy and Labour: A Fluid Balance Concept Study.","BiPAL","Inclusion Criteria: pregnant women at age of 16 or over with a viable pregnancy and who will fulfil the following:\n\n* Group I: Women attending for elective CS.\n* Group II: Women admitted for induction of labour and expected to stay stay in hospital for more than 24 hours.\n* Group III: Maternal condition that could have direct impact on body fluid including:\n\n  1. Pre-eclampsia requiring hospital admission.\n  2. Hyperemesis gravidarum requiring hospital admission.\n  3. Major postpartum haemorrhage (equal or greater than 1000 ml following delivery).\n* Group IV: gestational age matched controls.\n\nExclusion criteria:\n\n* Maternal age less than 16 years at booking.\n* Women who are not capable of giving consent.\n* Women with learning disabilities\u002Fdifficulties.\n* Unable to speak or read English to the appropriate level.\n* Prisoners.\n* Any others deemed to belong to a vulnerable group.\n* Women who require pace maker or defibrillators.","16 Years",{"count":174,"type":22},900,"OBSERVATIONAL","The purpose of our study is to find out if using a simple bed side test can tell us information about changes that occur in women's body water content. We would like to check if certain medical conditions could affect body water contents.",[28],"2025-12-31",{"date":180,"type":38},"2026-01-05",{"date":182,"type":38},"2019-04-08",{"date":184,"type":22},"2029-02-14",{"name":186,"class":44},"University Hospitals, Leicester",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":16,"sex":17,"minAge":193,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":23,"phases":197,"briefSummary":191,"conditions":198,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":45},"100608855","an-open-label-trial-assessing-the-impact-of-a-hydration-formula-on-overall-health-100608855","NCT07206979","An Open Label Trial Assessing the Impact of a Hydration Formula on Overall Health","3.1 Inclusion\n\nParticipants must meet all the following criteria:\n\n* Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races.\n* Resides in the United States.\n\n3.2 Exclusion\n\nIndividuals who report any of the following during screening will be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding.\n* Unable to provide a valid US shipping address and mobile phone number\n* Unable to read and understand English.\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n\n  * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure.\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n\n  * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products.\n* Reports the current use of electrolyte and\u002For hydration supplements that may limit the effects of the study products.\n* Lack of reliable daily access to the internet.","21 Years","105 Years",{"count":196,"type":22},660,[25],[28],"2025-09-26",{"date":201,"type":38},"2025-10-03",{"date":203,"type":22},"2025-09-30",{"date":205,"type":22},"2026-09-30",{"name":207,"class":74},"Radicle Science",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":45},"100593396","feasibility-of-using-the-gatorade-sports-science-institute-gssi-labs-app-for-hydration-related-outcomes-100593396","NCT07005895","Feasibility of Using the Gatorade Sports Science Institute (GSSI) Labs App for Hydration Related Outcomes","Feasibility of Using the Gatorade Sports Science Institute (GSSI) Labs App for Hydration Related Outcomes: User Engagement and Individual Variability of Transdermal Optical Imaging Features Before and After Acute Fluid Ingestion","Inclusion Criteria:\n\n* 18-65 years of age, inclusive\n* Male or female. If female, subject is not pregnant, planning to get pregnant, or currently breast feeding\n* Able to speak, write, and read English\n* Provision of written consent to participate\n* Owns and wears an activity tracker daily, including during sleep, except when submerged underwater (i.e., swimming, bathing) and is willing to connect their device to the app, per GSSI Labs App requirements (Oura, WHOOP, Apple Watch, Garmin, Polar, Withings, or Fitbit).\n* Owns a bathroom scale\n* Able to drink 600mL (600 mL = 20 oz = 2 ½ cups) of water as directed.\n* Willing to avoid alcohol consumption 24 hours prior to study session(s)\n\nExclusion Criteria:\n\n* Subject is currently enrolled in a clinical trial or has participated in a clinical trial within the past 30 days.\n* Subject is employed by, or has a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If subject is unsure if a company would be considered a competitor to Gatorade, they will be asked to please let the study investigator know the name of the other company and the nature of their relationship to that company before they sign the informed consent.","65 Years",{"count":217,"type":22},200,"This remote study will evaluate the feasibility of using the Gatorade Sports Science Institute (GSSI) Labs App for remotely collecting hydration related outcomes.",[28],[221,222,223,224],"transdermal optical imaging","TOI","app","user engagement","2025-05-27",{"date":227,"type":38},"2025-06-05",{"date":229,"type":38},"2025-05-06",{"date":231,"type":22},"2025-12-30",{"name":73,"class":74},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":249,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":45},"100520857","potassium-hydration-cardiovascular-and-kidney-study-phacks-100520857","NCT06062017","Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)","The Effects of Water and Potassium Supplementation on Cardiovascular and Kidney Function in Young Adults","PHACKs","Inclusion Criteria:\n\n* Between the ages of 18-30 years\n* Resting blood pressure no higher than 150\u002F90 mmHg\n* BMI below 35 kg\u002Fm2\n* Free of any metabolic disease (e.g., diabetes) kidney disease, pulmonary disorders (e.g., COPD), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular), no autoimmune diseases, and no history of cancer.\n\nExclusion Criteria:\n\n* Have any precluding medical conditions (i.e. hemophilia) or medication (Pradaxa, Eliquis, etc.) that prevent participants from giving blood.\n* Are currently pregnant or trying to become pregnant.\n* take any of the following medications that are contraindicated with potassium supplementation:\n* Renin-angiotensin-aldosterone system (RAAS) blockers: Candesartan , Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan\n* Non -steroidal anti-inflammatory medications: Aspirin, Ibuprofen, Naproxen\n* Non-selective beta-blockers: Pindolol, Penbutolol, Oxprenolol, Propranolol, Nadolol, Sotalol, Timolol, Tertatolol\n* Calcineurin inhibitors: Cyclosporine\n* Heparin (or other blood thinning medications)","30 Years",{"count":243,"type":22},40,[25],"Compared with White Adults, Non-Hispanic Black Adults are at an elevated risk of developing cardiovascular disease (CVD) and end stage chronic-kidney disease (CKD), two of the leading causes of death in the United States. Inadequate hydration status is associated with risk factors for both CVD and CKD. Prior data show that Black individuals are less likely to be adequately hydrated when compared with their White counterparts. Further, socioeconomic factors have been shown to influence hydration practices. Inadequate hydration influences certain hormones that regulate blood volume and impact blood pressure, but increasing potassium intake may provide some positive effects on normalizing these hormones and blood pressure. Black adults, in particular, are more likely to consume less potassium, have inadequate hydration, and tend to have higher blood pressure. As such, there is a critical need for effective strategies to address racial disparities in hydration and resultant health consequences; as well as establish the role of socioeconomic factors contributing to hydration. Therefore, the investigators are seeking to test the investigators' central hypothesis that water with a potassium supplement will improve hydration and cardiovascular health in young White adults (n = 20, 10 females, 10 males), and to a greater extent in young Black Adults (n = 20, 10 females, 10 males. The investigators will assess measures of blood pressure, arterial stiffness, and biomarkers in the urine and blood samples prior to and following a 14-day hydration intervention of 1) bottled water and 2) bottled water with potassium supplementation (2000mg potassium\u002Fday).",[247,28,248],"Blood Pressure","Vascular Disease Risk",[250,28,251,252,253],"Racial disparities","Blood pressure","Vascular function","Potassium","2025-02-25",{"date":256,"type":38},"2025-02-27",{"date":258,"type":38},"2024-11-06",{"date":260,"type":22},"2027-07",{"name":262,"class":44},"Auburn University"]